CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

Files in this item

This item appears in the following Collection(s)

© 2019 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society Except where otherwise noted, this item's license is described as © 2019 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement